UPDATE 1-Alkermes posts narrower-than-expected Q3 loss

* Q3 adj loss/shr $0.03 vs. est loss/shr $0.16

* Q3 GAAP loss/shr $0.07

* Q3 rev $44.2 million vs. est $39.65 mln

Feb 4 (BestGrowthStock) – Alkermes Inc (ALKS.O: ) posted a
narrower-than-expected quarterly loss on strong revenues from
its anti-psychotic schizophrenia drug, Risperdal.

Net loss for the third quarter was $6.8 million, or 7 cents
per share, compared to a net income of $112.7 million or $1.18
per share, in the year ago quarter.

Excluding items, but including stock based compensation,
the company posted a loss of 3 cents per share, according to
Thomson Reuters I/B/E/S.

Revenue for the quarter fell 71 percent to $44.2 million,
the company said in a statement.

Analysts on average were expecting the company to post a
loss of 16 cents a share, on revenue of $39.7 million.

Shares of the company closed at $10.52 Thursday on Nasdaq.

Investment

(Reporting by Krishnakali Sengupta in Bangalore; Editing by
Anthony Kurian)

UPDATE 1-Alkermes posts narrower-than-expected Q3 loss